Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on inflammatory cytokines of urogenital tissue in a rat model of type 2 diabetes (T2DM) to infer pharmaceutical influence of dapagliflozin on genitourinary infection or inflammation. Methods: Study animals were divided into the following 4 groups of 10 animals each: (1) the Otsuka Long-Evans Tokushima Fatty (OLETF)-DA group treated with dapagliflozin at 1.0 mg/kg/day, (2) the OLETF-VO group treated with voglibose at 0.6 mg/kg/day, (3) the control group (OLETF-CO) given water, and (4) the Long-Evans Tokushima Otsuka (LETO) rats were included as nondiabetic control group. Changes in blood glucose, 24-hour urine volume, and urine glucose were measured. The interleukin-1β (IL-1β) and interleukin-18 (IL-18) levels in the bladder and the urethra were quantified, respectively. Results: The urine glucose level and the 24-hour urine volume at 12 weeks of treatment were significantly higher in the OLETF-DA group than that in any other group (P<0.05). The cytokine analysis of the bladder and urethra showed higher IL18 and IL-1β in the OLETF-DA and the OLETF-CO groups than that in the OLETF-VO and LETO groups (P<0.05). The cytokine levels did not differ between the OLETF-DA and the OLETF-CO groups, and the level of IL-18 in the OLETF-DA group was higher in the urethra than in the bladder. Conclusions: This study revealed that dapagliflozin increased the urine glucose concentration, resulting in an inflammatory response remain in the urogenital tract as the untreated diabetic rats. Therefore, when treating patients with T2DM with dapagliflozin, careful attention should be paid to genitourinary infection or inflammation.
Abstract
Purpose: To investigate the effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on inflammatory cytokines of urogenital tissue in a rat model of type 2 diabetes (T2DM) to infer pharmaceutical influence of dapagliflozin on genitourinary infection or inflammation. Methods: Study animals were divided into the following 4 groups of 10 animals each: (1) the Otsuka Long-Evans Tokushima Fatty (OLETF)-DA group treated with dapagliflozin at 1.0 mg/kg/day, (2) the OLETF-VO group treated with voglibose at 0.6 mg/kg/day, (3) the control group (OLETF-CO) given water, and (4) the Long-Evans Tokushima Otsuka (LETO) rats were included as nondiabetic control group. Changes in blood glucose, 24-hour urine volume, and urine glucose were measured. The interleukin-1β (IL-1β) and interleukin-18 (IL-18) levels in the bladder and the urethra were quantified, respectively. Results: The urine glucose level and the 24-hour urine volume at 12 weeks of treatment were significantly higher in the OLETF-DA group than that in any other group (P<0.05). The cytokine analysis of the bladder and urethra showed higher IL18 and IL-1β in the OLETF-DA and the OLETF-CO groups than that in the OLETF-VO and LETO groups (P<0.05). The cytokine levels did not differ between the OLETF-DA and the OLETF-CO groups, and the level of IL-18 in the OLETF-DA group was higher in the urethra than in the bladder. Conclusions: This study revealed that dapagliflozin increased the urine glucose concentration, resulting in an inflammatory response remain in the urogenital tract as the untreated diabetic rats. Therefore, when treating patients with T2DM with dapagliflozin, careful attention should be paid to genitourinary infection or inflammation.
참고문헌 (36)
- Carey IM, "Risk of infection in type 1 and type 2 diabetes compared with the general population : a matched cohort study", Diabetes Care, 41, pp.513~521 (2018)
- Nitzan O, "Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management", Diabetes Metab Syndr Obes, 8, pp.129~136 (2015)
- Chen SL, "Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models", J Urol, 182(6 Suppl), pp.S51~S56 (2009)
- Casqueiro J, "Infections in patients with diabetes mellitus : a review of pathogenesis", Indian J Endocrinol Metab, 16(Suppl1), pp.S27~S36 (2012)
- Hosking DJ, "Diabetic autonomic neuropathy", Diabetes, 27, pp.1043~1055 (1978)
- Wang MC, "Bacterial characteristics and glycemic control in diabetic patients with Escherichia coli urinary tract infection", J Microbiol Immunol Infect, 46, pp.24~29 (2013)
- Fünfstück R, "Urinary tract infection in patients with diabetes mellitus", Clin Nephrol, 77, pp.40~48 (2012)
- Rahmoune H, "Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes", Diabetes, 54, pp.3427~3434 (2005)
- 정창희, "A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor", Diabetes and Metabolism Journal, 38(4), pp.261~273 (2014), 대한당뇨병학회[DOI]
- Meng W, "Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes", J Med Chem, 51, pp.1145~1149 (2008)
- Plosker GL, "Dapagliflozin : a review of its use in type 2 diabetes mellitus", Drugs, 72, pp.2289~2312 (2012)
- Storgaard H, "Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes : a systematic review and meta-analysis", PLoS One, 11, pp.e0166125~ (2016)
- Puckrin R, "SGLT-2 inhibitors and the risk of infections : a systematic review and meta-analysis of randomized controlled trials", Acta Diabetol, 55, pp.503~514 (2018)
- Zhang YJ, "Efficacy and safety of empagliflozin for type 2 diabetes mellitus: metaanalysis of randomized controlled trials", Medicine(Baltimore), 97, pp.e12843~ (2018)
- Melnick S, "Perioperative genitourinary infection associated with sodium-glucose co-transporter 2inhibitor use", J Community Hosp Intern Med Perspect, 8, pp.315~316 (2018)
- Liu J, "Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus : a systematic review and meta-analysis", Sci Rep, 7, pp.2824~ (2017)
- Gadzhanova S, "Use of SGLT2 inhibitors for diabetes and risk of infection : analysis using general practice records from the NPS MedicineWise MedicineInsight program", Diabetes Res Clin Pract, 130, pp.180~185 (2017)
- Li D, "Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors : a meta-analysis of randomized controlled trials", Diabetes Obes Metab, 19, pp.348~355 (2017)
- Sano M, "Hemodynamic effects of sodium-glucose cotransporter 2inhibitors", J Clin Med Res, 9, pp.457~460 (2017)
- Liu XY, "Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes : a metaanalysis of randomized controlled trials for 1 to 2years", J Diabetes Complications, 29, pp.1295~1303 (2015)
- Spencer JD, "The innate immune response during urinary tract infection and pyelonephritis", Pediatr Nephrol, 29, pp.1139~1149 (2014)
- Zhang JM, "Cytokines, inflammation, and pain", Int Anesthesiol Clin, 45, pp.27~37 (2007)
- Kawano K, "OLETF(Otsuka Long-Evans Tokushima Fatty)rat : a new NIDDM rat strain", Diabetes Res Clin Pract, 24(Suppl), pp.S317~S320 (1994)
- Dabhi AS, "Voglibose : an alpha glucosidase inhibitor", J Clin Diagn Res, 7, pp.3023~3027 (2013)
- Han S, "Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats", Diabetes, 57, pp.1723~1729 (2008)
- Kim JW, "Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes", J Cell Biochem (2018)[DOI]
- Maurer TS, "Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology", AAPS J, 13, pp.576~584 (2011)
- Staples E, "Optimising the quantification of cytokines present at low concentrations in small human mucosal tissue samples using Luminex assays", J Immunol Methods, 394, pp.1~9 (2013)
- Mukherjee S, "Early TBI-Induced cytokine alterations are similarly detected by two distinct methods of multiplex assay", Front Mol Neurosci, 4, pp.21~ (2011)
- Wilding JP, "A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers : applicability of a novel insulin-independent treatment", Diabetes Care, 32, pp.1656~1662 (2009)
- Bailey CJ, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial", Lancet, 375, pp.2223~2233 (2010)
- Kaku K, "Efficacy and safety of dapagliflozin as a monotherapy for type 2diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebocontrolled trial", Diabetes Obes Metab, 15, pp.432~440 (2013)
- Martinon F, "The inflammasome : a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta", Mol Cell, 10, pp.417~426 (2002)
- Purves JT, "Inflammasomes in the urinary tract : a disease-based review", Am J Physiol Renal Physiol, 311, pp.F653~62 (2016)
- Agace W, "Selective cytokine production by epithelial cells following exposure to Escherichia coli", Infect Immun, 61, pp.602~609 (1993)
- Smaldone MC, "Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis", Urology, 73, pp.421~426 (2009)